Seelos Therapeutics

Seelos Therapeutics

Private Company
Public Company
Subsidiary of
Clinical Trials, R&D

About

Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases. Our trials are designed to further evaluate the safety and efficacy of our acquired assets. These come to Seelos with well characterized efficacy and safety, thereby avoiding much of the lengthy and burdensome process of preclinical R&D.
By working with clinically ready novel and reformulated compounds we will move from asset acquisition to meaningful data readouts in an expedited and efficient fashion. It is our goal to develop unique and disruptive therapies and approaches to improve treatment of large known diseases, offer new treatments for large unmet or recently characterized indications as well as advance therapies for orphan indications. Our approach to this process will require development that is appropriate and efficient for a company our size in the scope of work each program requires in regards to trial size and duration.
Our senior leadership team members at Seelos Therapeutics are passionate, empowered, experienced, and committed to building our responsibly-driven company focused on the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Seelos Clinical Trials Focus August 2020

Management Team

Our senior leadership team members at Seelos Therapeutics are passionate, empowered, experienced, and committed to building our responsibly-driven company focused on the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.


Seelos Management February 2021

Board of Directors

Seelos Board August 2020